全口服抗病毒治疗对丙型肝炎病毒相关肝硬化患者肝静脉压力梯度及全身血流动力学的影响
多中心前瞻性研究纳入226例西班牙丙型肝炎病毒相关肝硬化伴临床显著门脉高压且获得持续病毒学应答的患者,比较治疗前与治疗后24周的血流动力学变化。持续病毒学应答后肝静脉压力梯度从15 mmHg降至13 mmHg,但78%患者临床显著门脉高压持续存在,肝硬度变化与肝静脉压力梯度不相关,肝硬度临界值不能可靠排除临床显著门脉高压。
要点
- 持续病毒学应答后肝静脉压力梯度下降2.1±3.2 mmHg,但78%患者临床显著门脉高压持续存在。
- 治疗后肝硬度降至13.6 kPa以下的患者中,仍有三分之一存在临床显著门脉高压。
- 基线白蛋白低于3.5 g/dL是肝静脉压力梯度下降≥10%的唯一负面因素。
核心结论
- 在丙型肝炎病毒相关肝硬化患者中,全口服治疗获得持续病毒学应答后肝静脉压力梯度较治疗前显著降低,但大多数患者临床显著门脉高压持续存在,提示仍有肝功能失代偿风险。
- 在该人群中,肝硬度变化与肝静脉压力梯度不相关,肝硬度临界值不能可靠排除持续病毒学应答后的临床显著门脉高压。
研究设计与样本
- 多中心前瞻性研究,纳入西班牙6个肝病单元226例丙型肝炎病毒相关肝硬化伴临床显著门脉高压且接受无干扰素治疗获得持续病毒学应答的患者。
- 在基线和治疗后24周测定肝静脉压力梯度、右心导管及肝硬度。
主要发现
- 75%患者有食管静脉曲张,21%为Child-B级,29%至少有1次既往肝功能失代偿发作。
- 肝静脉压力梯度从治疗前15(IQR:12-18)mmHg降至持续病毒学应答后13(10-16)mmHg,下降2.1±3.2 mmHg,P<.01;但78%患者临床显著门脉高压持续存在,140例(62%)肝静脉压力梯度较基线下降≥10%。
- 肝硬度从治疗前27(20-37)kPa降至持续病毒学应答后18(14-28)kPa,P<.05;肝硬度降至13.6 kPa以下的患者中三分之一仍存在临床显著门脉高压。
- 基线肝静脉压力梯度较高和治疗后肝硬度下降较少与持续病毒学应答后临床显著门脉高压持续存在相关;持续病毒学应答后全身血流动力学改善。
- 基线时13例患者存在肺动脉高压,持续病毒学应答后为25例,但仅3例患者肺血管阻力升高。
关键数值与推荐
- 临床显著门脉高压定义为肝静脉压力梯度≥10 mmHg。
- 基线白蛋白低于3.5 g/dL是肝静脉压力梯度下降≥10%的唯一负面因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with hepatitis C virus-associated cirrhosis and clinical significant portal hypertension (CSPH, hepatic venous pressure gradient [HVPG] 10 mmHg or greater), despite achieving sustained virological response (SVR) to therapy, remain at risk of liver decompensation. We investigated hemodynamic changes following SVR in patients with CSPH and whether liver stiffness measurements (LSMs) can rule out the presence of CSPH. METHODS: We performed a multicenter prospective study of 226 patients with hepatitis C virus-associated cirrhosis and CSPH who had SVR to interferon-free therapy at 6 Liver Units in Spain. The portal pressure gradient was determined based on HVPG at baseline and 24 weeks after therapy; patients also underwent right-heart catheterization and LSM at these time points. Primary outcomes were effects of SVR on the hepatic, pulmonary, and systemic hemodynamics; factors related to HVPG ≥10% reduction and to CSPH persistence; and whether LSMs can rule out the presence of CSPH after SVR. RESULTS: Most patients (75%) had esophageal varices, 21% were Child-B, and 29% had at least 1 previous episode of liver decompensation. Overall, HVPG decreased from 15 (IQR: 12-18) before treatment to 13 (10-16) mmHg after SVR (reduction of 2.1 ± 3.2 mmHg; P < .01). However, CSPH persisted in 78% of patients. HVPG decreased by 10% or more from baseline in 140 patients (62%). Baseline level of albumin below 3.5 g/dL was the only negative factor associated with an HVPG reduction of 10% or more. LSM decreased from 27 (20-37) kPa before treatment to 18 (14-28) kPa after SVR (P < .05). One third of patients with a reduction in LSM to below 13.6 kPa after SVR still had CSPH. A higher baseline HVPG and a lower decrease in LSM after treatment were associated with persistence of CSPH after SVR. Systemic hemodynamics improved after SVR. Interestingly, pulmonary hypertension was present in 13 patients at baseline and 25 after SVR, although only 3 patients had increased pulmonary resistance. CONCLUSIONS: In a multicenter prospective study of patients with hepatitis C virus-associated cirrhosis, an SVR to all-oral therapy significantly reduced HVPG, compared with before treatment. Nevertheless, CSPH persists in most patients despite SVR, indicating persistent risk of decompensation. In this population, changes in LSM do not correlate with HVPG and cut-off values are not reliable in ruling out CSPH after SVR.
引用
- Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology. 2017. PMID: 28734831. doi:10.1053/j.gastro.2017.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。